ArticleFrontiers in oncology2022

Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer.

Daniel R Principe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.